May 28 (Reuters) - Drug developer iTeos Therapeutics ITOS.O said on Wednesday it plans to wind down its operations and explore selling its assets, including experimental cancer treatments and an obesity program.
Earlier this month, Britain's GSK GSK.L and iTeos Therapeutics said they have stopped developing an experimental lung cancer drug, belrestotug, after it failed to stop the disease from progressing in two studies.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shreya Biswas)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.